olivLaw · US equity research
Lucid Diagnostics Inc. LUCD
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
Lucid Diagnostics develops EsoGuard, a DNA test for detecting esophageal precancer in patients with chronic GERD, used together with the EsoCheck cell collection device. The company is at an early commercial stage: it recorded revenue of 4.7 million USD in 2025 and 1.5 million USD in the second quarter of 2026, while Medicare coverage is still pending, making the transition to reimbursement the main factor to watch.
At the close of 05 Nov 2026, Lucid Diagnostics Inc. (LUCD) stock was 0.39 USD (−12.34% on the day), with market capitalisation 79.3 m USD, beta 0.91, 52-week range 0.33–1.47 USD. Latest reported quarter (Q2 2026): revenue of 1.5 m USD (+26.7% YoY), net income of -11.7 m USD, diluted EPS -0.08 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 36.6
- weak (30–45)
- Bollinger (20, 2)
- 0.28 – 0.63
- in the lower half of the band · %B 0.33 · band width 77.9%
- SMA 50 / 200
- 0.67 / 1.01
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.07 / -0.09
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −35.0% | −1.1% | −33.9 pp | — |
| 3 months | −59.1% | −0.5% | −58.6 pp | — |
| 6 months | −62.8% | +4.4% | −67.2 pp | — |
| Year to date | −64.2% | +12.3% | −76.5 pp | — |
| 1 year | −64.9% | +13.5% | −78.4 pp | −30.5% |
| 3 years | −69.8% | +76.4% | −146.2 pp | −9.6% |
| 5 years | −95.9% | +63.7% | −159.6 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2 m | 1.2 m | 828.0 k | 1.2 m | 1.2 m | 1.5 m | 1.3 m | 1.5 m |
| Cost of revenue | — | — | 1.6 m | 1.6 m | — | — | 1.6 m | 1.4 m |
| Research & development | 1.7 m | 1.5 m | 1.4 m | 1.3 m | 1.3 m | 1.7 m | 1.2 m | 1.2 m |
| Operating income | -11.7 m | -12.4 m | -12.5 m | -11.4 m | -11.8 m | -14.0 m | -12.1 m | -12.8 m |
| Depreciation & amortisation | 215.0 k ≈ | 222.0 k | 221.0 k | 222.0 k ≈ | 220.0 k ≈ | 209.0 k | 222.0 k | 224.0 k ≈ |
| Interest expense | 1.0 k | 7.0 k | 9.0 k | 6.0 k | 2.0 k | 6.0 k | 6.0 k | 4.0 k |
| Pre-tax income | -12.4 m | -11.5 m | -26.9 m | -4.4 m | -10.4 m | -16.3 m | -13.9 m | -11.7 m |
| Income tax | — | — | 0 | 0 | — | — | 0 | 0 |
| Net income | -12.4 m | -11.5 m | -26.9 m | -4.4 m | -10.4 m | -16.3 m | -13.9 m | -11.7 m |
| Diluted EPS | -0.25 | -0.20 ≈ | -0.52 | -0.08 | -0.10 | — | -0.17 | -0.08 |
| Operating cash flow | -10.2 m ≈ | -9.9 m | -12.5 m | -10.5 m ≈ | -10.9 m ≈ | -12.6 m | -12.1 m | -11.3 m ≈ |
| Capex | — | — | 93.0 k | 25.0 k ≈ | — | — | 215.0 k | 21.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | unavailable | 500.0 k | 377.0 k | 2.4 m | 4.3 m | 4.7 m |
| Revenue YoY | unavailable | unavailable | −24.6% | +544.0% | +79.0% | +8.3% |
| Net income | -8.3 m | -28.1 m | -56.2 m | -52.7 m | -45.5 m | -58.0 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -1.51 | -1.55 | -1.26 | -1.05 | -0.69 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | -5,615.6% | -14,899.5% | -2,169.1% | -1,047.6% | -1,232.7% |
| Free cash flow | unavailable | -18.5 m | -32.9 m | unavailable | -44.4 m | -46.7 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- unavailable USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 10.9 m USD
- Total assets
- 40.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.31x
- ROE
- -710.6%
- ROA
- -163.0%
- FCF margin
- -992.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | — | 500.0 k | 377.0 k | 2.4 m | 4.3 m | 4.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Cost of revenue | — | 585.0 k | 100.0 m | — | 7.1 m | 6.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Gross profit | — | 500.0 k | 377.0 k | — | -2.8 m ≈ | -2.0 m ≈ | SEC (XBRL)· 25 Mar 2026derived |
| Research & development | 5.4 m | 9.3 m | 11.3 m | 7.3 m | 6.0 m | 5.7 m | SEC (XBRL)· 25 Mar 2026verified |
| SG&A | 7.0 k | 21.0 k | — | — | — | — | SEC (XBRL)· 06 Apr 2022verified |
| Operating income | -8.3 m | -27.4 m | -56.3 m | -48.5 m | -46.1 m | -49.6 m | SEC (XBRL)· 25 Mar 2026verified |
| Depreciation & amortisation | — | 4.0 k | 1.9 m | 2.5 m | 1.2 m | 872.0 k | SEC (XBRL)· 25 Mar 2026verified |
| EBITDA | — | -27.4 m ≈ | -54.3 m ≈ | -46.0 m ≈ | -44.9 m ≈ | -48.8 m ≈ | SEC (XBRL)· 25 Mar 2026derived |
| Interest expense | — | 659.0 k | 8.0 k | 416.0 k | 26.0 k | 22.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Pre-tax income | -8.3 m | -28.1 m | -56.2 m | -52.7 m | -45.5 m | -58.0 m | SEC (XBRL)· 25 Mar 2026verified |
| Income tax | — | — | — | — | 0 | 0 | SEC (XBRL)· 25 Mar 2026verified |
| Net income | -8.3 m | -28.1 m | -56.2 m | -52.7 m | -45.5 m | -58.0 m | SEC (XBRL)· 25 Mar 2026verified |
| Diluted EPS | — | -1.51 | -1.55 | -1.26 | -1.05 | -0.69 | SEC (XBRL)· 25 Mar 2026verified |
| Weighted average diluted shares | — | — | 36.2 m | 41.8 m | 50.5 m | — | SEC (XBRL)· 24 Mar 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | — | 53.7 m | 22.5 m | 18.9 m | 22.4 m | — | SEC (XBRL)· 24 Mar 2025verified |
| Receivables | — | 200.0 k | 17.0 k | 45.0 k | 45.0 k | 643.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Inventories | — | — | 111.0 k | 278.0 k | 341.0 k | 353.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Current assets | 1.4 m | 57.3 m | 24.4 m | 22.1 m | 25.1 m | 37.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Property, plant & equipment, net | — | 971.0 k | 1.6 m | 1.3 m | 1.1 m | 809.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Intangibles (excl. goodwill) | — | — | 3.4 m | 1.4 m | 736.0 k | 315.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Total assets | 2.2 m | 59.0 m | 32.5 m | 27.3 m | 30.7 m | 40.4 m | SEC (XBRL)· 25 Mar 2026verified |
| Accounts payable | 2.1 m | 1.5 m | 1.1 m | 1.1 m | 1.2 m | 970.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Long-term debt | 13.3 m | — | — | — | — | — | SEC (XBRL)· 23 Nov 2021verified |
| Current liabilities | — | 4.3 m | 8.4 m | 29.4 m | 23.5 m | 28.6 m | SEC (XBRL)· 25 Mar 2026verified |
| Total liabilities | 15.7 m | 4.3 m | 9.5 m | 29.6 m | 25.3 m | 29.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Equity | -13.5 m † | 54.7 m † | 23.0 m † | -2.3 m † | 5.4 m † | 10.9 m † | SEC (XBRL)· 25 Mar 2026verified |
| Shares outstanding at year end | — | — | — | — | 67.0 m | — | SEC (XBRL)· 24 Mar 2025verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -5.6 m | -17.7 m | -29.7 m | -32.8 m | -44.1 m | -46.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Capex | — | 862.0 k | 3.2 m | — | 296.0 k | 197.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Free cash flow | — | -18.5 m ≈ | -32.9 m ≈ | — | -44.4 m ≈ | -46.7 m ≈ | SEC (XBRL)· 25 Mar 2026derived |
| Investing cash flow | — | -862.0 k | -4.1 m | -221.0 k | -646.0 k | -197.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Financing cash flow | 5.6 m | 72.1 m | 2.6 m | 29.5 m | 48.2 m | 59.0 m | SEC (XBRL)· 25 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 79.3 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -959.8% | 6 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 132.0% | 100 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -2,815.8x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 1.3x | 44 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -59.5% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet18/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial6/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Lucid Diagnostics Inc. (LUCD). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 4.7 m USD in 2025; YoY growth 8.3%; net margin -959.8%; ROE -556.3%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 132.0%
What contradicts it
- Net margin: -959.8%
- Interest coverage: -2,815.8x
- FCF yield: -59.5%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 129.3 bn | 36.2 | 16.0% | 13.8% | +11.2% | −8% / +15% |
| MMM3m Company | 100.2 bn | 28.9 | 80.8% | 14.0% | +1.5% | +13% / +134% |
| BSXBoston Scientific Corporation | 66.4 bn | 19.4 | 14.3% | 16.6% | +19.9% | −55% / −18% |
| BDXBecton, Dickinson And Company | 57.0 bn | 63.2 | 3.8% | 4.0% | +8.2% | +37% / +13% |
| RMDResMed Inc. | 33.8 bn | 21.9 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 33.0 bn | 34.8 | 37.7% | 19.4% | +15.6% | +39% / −23% |
| WSTWest Pharmaceutical Services, Inc. | 28.5 bn | 45.9 | 21.2% | 18.8% | +6.3% | +47% / +17% |
| TFXTeleflex Incorporated | 6.4 bn | — | -28.9% | -45.8% | +17.2% | +33% / −33% |
| MMSIMerit Medical Systems Inc | 5.4 bn | 33.7 | 9.8% | 9.9% | +11.8% | +3% / +25% |
| IRTCiRhythm Holdings, Inc. | 4.3 bn | — | -9.6% | -1.7% | +26.2% | −31% / +53% |
| PLSEPulse Biosciences, Inc. | 3.8 bn | — | -78.5% | -6,755.8% | unavailable | +288% / +488% |
| AORTArtivion, Inc. | 1.2 bn | — | -0.7% | -0.7% | +13.6% | −46% / +43% |
| IRMDIradimed Corporation | 1.1 bn | 45.7 | 23.4% | 26.8% | +14.4% | −8% / +95% |
| BBNXBeta Bionics, Inc. | 842.1 m | — | -23.9% | -65.3% | +53.9% | −51% / unavailable |
| KIDSOrthoPediatrics Corp | 841.3 m | — | -9.8% | -12.8% | +15.4% | +74% / +5% |
| DCTHDelcath Systems, Inc. | 502.8 m | 1,168.8 | 0.5% | 0.6% | +129.1% | +49% / +427% |
| OBIOOrchestra BioMed Holdings, Inc. | 337.8 m | — | -601.8% | -184.6% | +1,169.2% | +6% / −10% |
| PROFProfound Medical Corp. | 251.3 m | — | -73.5% | -171.6% | +50.7% | +4% / −37% |
| PDEXPro-Dex, Inc. | 195.8 m | 16.9 | 26.5% | 15.1% | +16.5% | +68% / +279% |
| GUTSFractyl Health, Inc. | 142.6 m | — | — | — | −100.0% | −95% / unavailable |
| APYXApyx Medical Corp | 128.9 m | — | -96.4% | -14.8% | +9.9% | −24% / +30% |
| LUNGPulmonx Corporation | 111.5 m | — | -90.3% | -47.9% | +8.0% | +58% / −77% |
| LUCDLucid Diagnostics Inc. | 79.3 m | — | -556.3% | -959.8% | +8.3% | −65% / −70% |
| MBOTMicrobot Medical Inc. | 71.9 m | — | -32.9% | — | unavailable | −56% / −15% |
| RNXTRenovorx, Inc. | 53.7 m | — | -125.2% | -621.7% | +2,511.6% | +30% / +86% |
1- and 3-year price returns: for LUCD from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Lucid Diagnostics develops EsoGuard, a DNA test for detecting esophageal precancer in patients with chronic GERD, used together with the EsoCheck cell collection device. The company is at an early commercial stage: it recorded revenue of 4.7 million USD in 2025 and 1.5 million USD in the second quarter of 2026, while Medicare coverage is still pending, making the transition to reimbursement the main factor to watch.
SWOT
Strengths
- The company has reported analytical and clinical validation data for its test and a device with FDA and CE marks, strengthening its position in precancer diagnostics 1.
- Several professional societies already recommend non-endoscopic testing, giving a strong argument in discussions with insurers 1.
- The Department of Veterans Affairs contract and the new laboratory benefit manager policy show progress in market access 2.
Weaknesses
- Revenue remains very small, and operating costs and net losses are high relative to income 13.
- The company depends on a single product and a single license agreement with a university, concentrating risk 1.
- Reliance on equity and convertible financing can lead to dilution and pressure on cash flow 13.
Opportunities
- A favorable Medicare decision could open access to a large patient population and support commercial coverage 3.
- Ongoing studies in populations without GERD symptoms could widen the test's indications if results are positive 1.
- Partnerships with health systems and employers could increase test volume without expanding the company's own infrastructure 1.
Threats
- The emergence of new screening technologies could reduce EsoGuard's competitiveness or make it obsolete 1.
- If insurers do not cover the test, patients may pay out of pocket or not test at all, limiting adoption 1.
- Changes in rules on clinical laboratories and telemedicine could create compliance costs or penalties 1.
Risks
- Going concernhigh
The company has concluded there is substantial doubt about its ability to continue as a going concern, which could affect financing conditions 1.
- Medicare coveragehigh
If the LCD reconsideration does not produce a favorable outcome, revenue may remain limited to out-of-network commercial payments 13.
- Shareholder dilutionmedium
Convertible securities and future share issuances could reduce the stake of current shareholders and could change control of the company 1.
- Dependence on PAVmedmedium
PAVmed holds more voting stock than any other shareholder and conflicts of interest with affiliates exist, which could influence decisions 1.
- Regulatory compliancelow
Clinical laboratories, telemedicine and medical devices are subject to complex rules, and non-compliance could lead to fines 1.
Investment thesis
What would need to be true (bull case)
- If Medicare coverage becomes favorable, the potential market described by the company could be reached much faster than so far 13.
- Current clinical guidelines give solid support to non-endoscopic testing, which could speed physician adoption 1.
- Contracts with the veterans system and new commercial policies show market access advancing across several channels 23.
What would break the thesis
- Revenue remains modest compared with operating expenses, and the company's net loss remains significant 13.
- Without Medicare coverage, reliance on commercial payments could limit short-term revenue growth 1.
- Continued financing through shares and convertibles could dilute shareholders and reduce the company's flexibility 13.
What to watch
- Final MolDx decision on LCD L39256 and the Medicare policy for EsoGuardnext 10-K
- Trend in EsoGuard revenue and tests processed per quarterQ3 2026
- Results of the NIH and VA studies in the population without GERD symptoms2027
- Cash levels and any new share or convertible issuancesQ3 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Lucid Diagnostics is a commercial-stage cancer prevention diagnostics company focused on patients with gastroesophageal reflux disease (GERD) at risk of developing esophageal precancer and cancer, especially esophageal adenocarcinoma (EAC) 1. Its flagship product, the EsoGuard DNA test, is run on cells collected with the FDA 510(k)-cleared EsoCheck device in an office procedure of less than two minutes 1. The company is based in New York and is a subsidiary of PAVmed Inc. 3.
Its access model combines its own Lucid Test Centers, a satellite and mobile testing program, testing events with fire departments, a telemedicine channel, and direct contracts with employers and health systems 1. In 2025 it won a contract with the U.S. Department of Veterans Affairs, and in July 2026 it secured its first coverage policy from a laboratory benefit manager 2. Revenue comes mostly from commercial insurer payments received out of network 1.
Reimbursement depends on MolDx reconsidering LCD L39256; the company submitted its clinical evidence package in November 2024 and the advisory committee met in September 2025 13. Lucid says it is awaiting a positive draft Medicare coverage policy while pursuing commercial coverage in the meantime 3.
Segments
Market context
The company estimates the total addressable U.S. market for EsoGuard could approximate 60 billion USD, based on the Medicare payment and about 30 million patients recommended for screening by clinical guidelines 1. However, fewer than 5% of at-risk patients currently undergo endoscopy, which points to a substantial adoption gap 1.
The market size is the company's own estimate rather than a verified figure, and adoption depends on insurer coverage, which remains partial 12.
Trends
- Supportive clinical guidelinestailwind
ACG, AGA and NCCN now recognize non-endoscopic biomarker testing as an acceptable alternative to endoscopy, which could increase physician and payer acceptance 1.
- Wider target populationtailwind
The 2022 AGA guidance includes patients without GERD symptoms, and a 2025 pilot reported BE prevalence above 8% in this group, which could expand the market 1.
- Delayed Medicare coverageheadwind
Medicare reimbursement remains pending after the LCD reconsideration, and if the process is prolonged, revenue may stay limited to out-of-network commercial payments 13.
- Financing and dilutionmixed
The company has relied on equity and convertible securities, and an ATM program of up to 25 million USD could dilute existing shareholders 1.
Competitive position
The main alternative is invasive upper endoscopy with biopsy, used for at most 5% of at-risk patients, and the company argues EsoGuard is the first commercial test designed for widespread screening 1. Other direct precancer diagnostic players are not identified in the reviewed sources, so direct competition remains undefined here 1.
Lucid notes that non-endoscopic capsule devices such as EsoCheck are the closest alternatives, but the company claims it is the only one offering anatomically targeted and protected sampling 1.
- Upper endoscopy (EGD)
The standard invasive method for detecting Barrett's esophagus, rarely used in the at-risk population according to the company 1.
- Other non-endoscopic cell collection devices
The sources mention only EsoCheck by name; no other named competitors appear in the reviewed documents 1.
- Competing DNA methylation tests
Methylated DNA biomarkers are referenced as a general category in clinical guidelines, without named providers 1.
- Health system screening programs
Health systems offering integrated testing may compete for the same patients and budgets 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report22 Oct 2026Item 3.02 · Item 3.03 · Amendments to articles or bylaws · Financial statements and exhibits
- Current report16 Oct 2026Delisting notice · Financial statements and exhibits
- Current report22 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report13 Aug 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report12 Aug 2026
- Current report24 Jun 2026Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Current report14 May 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report13 May 2026
- Proxy statement30 Apr 2026
- Current report24 Apr 2026Regulation FD disclosure · Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Lucid Diagnostics Inc. · 25 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Lucid Diagnostics Inc. · 12 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Lucid Diagnostics Inc. · 13 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.